Anaptys Expands Immune Cell Modulator Pipeline With Exclusive License To BDCA2 Modulator Antibody Portfolio From Centessa Pharmaceuticals; Anaptys Will Pay Centessa A One-Time Upfront Cash Payment Of $7M
Portfolio Pulse from Benzinga Newsdesk
AnaptysBio, Inc. has secured an exclusive license for Centessa Pharmaceuticals' BDCA2 modulator antibody portfolio, including the lead asset CBS004 (to be renamed ANB101), for treating autoimmune and inflammatory diseases. Anaptys plans to file an IND for ANB101 in H2 2024 and expects to maintain a cash runway through 2026. The deal involves a $7M upfront payment from Anaptys to Centessa, with additional potential milestone payments and royalties on sales.
November 27, 2023 | 9:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AnaptysBio's exclusive license for Centessa's BDCA2 modulator portfolio could enhance its immunology pipeline, with IND filings for ANB101 expected in H2 2024. The company reiterates a strong cash position through 2026.
The license agreement is likely to be viewed positively as it expands AnaptysBio's pipeline with a potential best-in-class treatment for autoimmune diseases. The financial stability through 2026 reassures investors of the company's capacity to develop these assets.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Centessa Pharmaceuticals grants AnaptysBio an exclusive license to its BDCA2 modulator portfolio, receiving a $7M upfront payment and eligibility for future milestone payments and royalties.
Centessa Pharmaceuticals stands to benefit financially from the upfront payment and potential future earnings from milestone payments and royalties. This deal allows Centessa to monetize its BDCA2 portfolio while focusing on other projects.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70